Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization
The Prophylactic Use of Loratadine for Granulocyte-Colony Stimulating Factor (G-CSF) Induced Bone Pain in Multiple Myeloma Patients Undergoing Stem Cell Mobilization
Rutgers, The State University of New Jersey
70 participants
Apr 18, 2022
INTERVENTIONAL
Conditions
Summary
This early phase I trial studies how well loratadine works in reducing granulocyte-colony stimulating factor (G-CSF) induced bone pain in patients with multiple myeloma who are undergoing stem cell mobilization. Loratadine is an antihistamine that may help to reduce or control bone pain during the process of stem cell collection in patients with multiple myeloma.
Eligibility
Inclusion Criteria4
- Patient must be able to provide informed consent
- Patients with confirmed diagnosis of multiple myeloma
- Able to swallow and retain oral medication
- All ethnic groups are eligible
Exclusion Criteria5
- Non-English speaking person
- Patients undergoing haploidentical allogeneic hematopoietic stem cell transplant
- Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds
- Any medical complications or conditions that would, in the investigator's judgement, interfere with full participation in the study
- On therapeutic dose of aspirin (doses greater than 81 mg) within 7 days prior to the start of the study
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Given PO
Given PO
Ancillary studies
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04211259